Федеральные клинические рекомендации по клинике, диагностике, дифференциальной диагностике и методам лечения акромегалии

Клинические рекомендации были составлены Г.А. Мельниченко, Н.Н. Молитвослововой, Л.Я. Рожинской, И.И. Дедовым в мае 2013 г. В июне 2013 г. разосланы всем остальным членам рабочей группы (состав рабочей группы представлен ниже), были получены дополнения и замечания, которые внесены и учтены, затем вновь разосланы членам рабочей группы, получено их согласие на публикацию. В июле 2013 г. рекомендации были направлены рецензентам, в августе 2013 г. получены от всех рецензентов положительные отзывы, после чего клинические рекомендации были опубликованы на сайте Российской ассоциации эндокринологов для дальнейшего обсуждения

Рабочая группа по созданию Клинических рекомендаций по акромегалии Российской ассоциации эндокринологов

• И.И. Дедов, акад. РАН и РАМН, Москва
• Г.А. Мельниченко, акад. РАМН, проф., Москва
• Н.Н. Молитвослова, д.м.н., Москва

1. Дедов И.И., Мельниченко Г.А. Акромегалия: патогенез, клиника, диагностика, дифференциальная диагностика, методы лечения. Пособие для врачей. М 2012.

2. Молитвословова Н.Н., Рожинская Л.Я., Мельниченко Г.А. Российский консенсус по диагностике, лечению и мониторингу акромегалии (проект). Пробл эндокринол 2007; 53: 4: 37-42.

3. Melmed S., Colao A., Barkan A., Molitch M., Grossman A.B., Kleinberg D., Clemmons D., Chanson P., Laws E., Schlechte J., Vance M.L., Ho K., Giustina A. Acromegaly Consensus Group. Guidelines for acromegaly management: an update. J Clin Endocrinol Metabol 2009; 94: 5: 1509-1517. doi: 10.1210/jc.2008-2421.

4. Giustina A., Chanson P., Bronstein M.D., Klibanski A., Lamberts S., Casanueva F.F., Trainer P., Ghigo E., Ho K., Melmed S., Acromegaly Consensus Group. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metabol 2010; 95: 7: 3141-3148. doi: 10.1210/jc.2009-2670.

5. Melmed S., Casanueva F.F., Klibanski A., Bronstein M.D., Chanson P., Lamberts S.W., Strasburger C.J., Wass J.A., Giustina A. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 2012.

6. Katznelson L., Atkinson J.L., Cook D.M., Ezzat S.Z., Hamrahian A.H., Miller K.K. AACE Acromegaly Task Force. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Acromegaly-2011 update: executive summary. Endocr Pract 2011; 17: 4: 636-646.

7. Ronchi C.L., Boschetti M., Degli Uberti E.C., Mariotti S., Grottoli S., Loli P., Lombardi G., Tamburrano G., Arvigo M., Angeletti G., Boscani P.F., Beck-Peccoz P., Arosio M. Italian Multicenter Autogel Study Group in Acromegaly. Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study. Clin Endocrinol (Oxf) 2007; 67: 4: 512-519.

8. Le Corvoisier P., Hittinger L., Chanson P., Montagne O., Macquin-Mavier I., Maison P. Cardiac effects of growth hormone treatment in chronic heart failure: A meta-analysis. J Clin Endocrinol Metabol 2007; 92: 1: 180-185.

9. Melmed S., Sternberg R., Cook D., Klibanski A., Chanson P., Bonert V., Vance M.L., Rhew D., Kleinberg D., Barkan A. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metabol 2005; 90: 7: 4405-4410.

10. Caron P., Bevan J., Clermont A., Maisonobe P. Early and sustained tumour volume reduction and GH/IGF1 control in patients with GH-secreting pituitary macroadenoma primarily treated with lanreotide Autogel 120 mg for 48 weeks: the PRIMARYS study. The 15th European congress of Endocrinology. Endocrinology 2013.

11. Melmed S., Cook D., Schopohl J., Goth M.I., Lam K.S., Marek J. Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension. Pituitary 2010; 13: 1: 18-28.

12. Andries M., Glintborg D., Kvistborg A., Hagen C., Andersen M. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly. Clin Endocrinol (Oxf) 2008; 68: 3: 473-480.

13. Croxtall J.D., Scott L.J. Lanreotide Autogel: a review of its use in the management of acromegaly. Drugs 2008; 68: 5: 711-723.

14. Murray R.D., Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metabol 2008; 93: 8: 2957-2968. doi: 10.1210/jc.2008-0027.

15. Roelfsema F., Biermasz N.R., Pereira A.M., Romijn J.A. Therapeutic options in the management of acromegaly: focus on lanreotide Autogel. Biologics 2008; 2: 3: 463-479.

16. Lucas T., Astorga R. Spanish-Portuguese Multicentre Autogel Study Group on Acromegaly. Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial. Clin Endocrinol (Oxf) 2006; 65: 3: 320-326.

17. Schopohl J., Strasburger C.J., Caird D., Badenhoop K., Beuschlein F., Droste M., Plöckinger U., Petersenn S. German Lanreotide Study Group. Efficacy and acceptability of lanreotide Autogel 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR. Exp Clin Endocrinol Diabetes 2011; 119: 3: 156-162.

18. Bevan J.S., Newell-Price J., Wass J.A., Atkin S.L., Bouloux P.M., Chapman J., Davis J.R., Howlett T.A., Randeva H.S., Stewart P.M., Viswanath A. Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective. Clin Endocrinol (Oxf) 2008; 68: 3: 343-349.

19. Caron P., Cogne M., Raingeard I., Bex-Bachellerie V., Kuhn J.M. Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly. Clin Endocrinol (Oxf) 2006; 64: 2: 209-214.

20. Gutt B., Bidlingmaier M., Kretschmar K. et al. Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel). Exp Clin Endocrinol Diabetes 2005; 113: 3: 139-144.

21. Florio T., Thellung S., Corsaro A. et al. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro. Clin Endocrinol (Oxf) 2003; 59: 115-128.

22. Wasko R., Jankowska A., Kotwicka M., Liebert W., Sowinski J., Warchol J.B. Effects of treatment with somatostatin analogues on the occurrence of apoptosis in somatotropinomas. Neuro Endocrinol Lett 2003; 24: 5: 334-338.

23. Alexopoulou O., Abrams P., Verhelst J. et al. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur J Endocrinol 2004; 151: 317-324.

24. Attanasio R., Lanzi R., Losa M. et al. Effects of lanreotide Autogel on growth hormone, insulinlike growth factor 1, and tumor size in acromegaly: a 1-year prospective multicenter study. Endocrinol Pract 2008; 14: 7: 846-855.

25. Baldelli R., Ferretti E., Jaffrain-Rea M. et al. Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients. J Clin Endocrinol Metabol 1999; 84: 527-532.

26. Hradec J., Krai J., Janota T. et al. Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog). Am J Cardiol 1999; 83: 1506-1509.

27. Lombardi G., Colao A., Marzullo P. et al. Multicenter Italian Study Group on Lanreotide. Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study. J Endocrinol Invest 2002; 25: 11: 971-976.

28. Magyar D.M., Marshall J.R. Pituitary tumors and pregnancy. Am J Obstet Gynecol 1978; 132: 739-751.